What Is Wegovy Like in Practice? A Realistic Guide

Step 1, The first injection and the starter weeks (0.25mg)

The pen itself is smaller than most people expect. Each pre-filled device delivers one dose; you inject once a week into the abdomen, thigh or upper arm, rotating the site each time. The mechanics take a minute to learn and quickly become routine. A question our prescribers hear most weeks is whether the first injection will cause immediate side effects, the honest answer is that it often causes very little, which is exactly the point. The 0.25mg starting dose is a tolerability phase: your system is being introduced to the medicine, not yet treated by it.

In these early weeks many people notice a slight reduction in appetite without fully understanding why they feel satisfied sooner. Others notice almost nothing. That is normal. The dose is low by design, and the titration schedule exists because rushing to a higher level too quickly is associated with more nausea. The detailed experience guide explores the first weeks in more depth if you want a fuller picture of what people report.

Step 2 (Appetite changes and GI effects as the dose climbs

Each dose increase) 0.5mg, then 1mg, then 1.7mg, then 2.4mg, typically a month apart, tends to bring a fresh wave of adjustment. Nausea is the most commonly reported side effect, followed by constipation, diarrhoea, reflux and burping. These tend to peak in the first few days after a new dose and settle within one to two weeks for most people. Eating smaller portions, avoiding fatty or rich food around injection day, and staying well-hydrated all help. Fatigue and mild headaches are also reported during adjustment periods.

The semaglutide information page covers the full safety profile in detail. It is worth knowing that the NHS medicines page for semaglutide notes these GI effects are expected and generally transient, they are not a sign that the medicine is harming you, though persistent or severe symptoms should always be discussed with your prescriber. The MHRA highlighted in January 2026 that acute pancreatitis is an infrequent but serious effect requiring immediate medical attention if you experience severe stomach pain spreading to the back.

What many people also describe (and find surprising) is a changed relationship with food more broadly. Cravings for high-calorie foods tend to reduce. Portion sizes that once felt modest now feel sufficient. Some describe this as the mental quiet they had not expected.

Step 3, Life at the maintenance dose

At 2.4mg, most people have found a steady rhythm. The injection is weekly, the appetite change is consistent, and the GI effects have typically settled compared to the adjustment phases. In the first-person experience accounts people share with our team, the phrase that comes up repeatedly is that hunger feels manageable rather than absent. Wegovy does not switch appetite off entirely; it turns the volume down.

Weight loss at this stage tends to be steady rather than rapid. The STEP 1 trial, published in the New England Journal of Medicine, recorded an average reduction of around 15% of body weight over 68 weeks at the 2.4mg dose alongside lifestyle changes. Results vary by individual; no specific outcome can be predicted for any one person. The MHRA approved a higher 7.2mg maintenance dose in January 2026 and the dedicated single-dose 7.2mg pen in April 2026, which trials associated with around 20.7% average weight loss over 72 weeks, worth discussing with a prescriber if you want to understand whether it might be relevant for you.

Storage is straightforward: the pen lives in the fridge. The exact room-temperature window if you are travelling is detailed in the Patient Information Leaflet; always check the leaflet rather than a general guide, because that detail matters. What the semaglutide pen looks like is a practical question with a practical answer if you have not seen one before.

Who Wegovy is licensed for, and the cost context

The UK licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. It is not licensed for under-18s, and it is not recommended during pregnancy or breastfeeding, or for anyone trying to conceive. A prescriber assesses the full clinical picture before any prescription is issued; BMI alone does not guarantee approval.

On the NHS, Wegovy is available through specialist weight management services under NICE guidance (TA875), though waiting lists are commonly long. Private treatment is the route most people use to begin without delay, and the weight-loss treatment overview covers how that works. For anyone comparing costs across providers, the Wegovy cost page sets out what a legitimate private price typically includes: consultation, prescription, clinical review and aftercare. According to NHS guidance on semaglutide, this is a prescription-only medicine requiring proper clinical assessment, that requirement does not disappear because a price looks attractive.

If you are ready to find out whether Wegovy is clinically suitable for you, the next step is a free consultation with a GPhC-registered prescriber. Check your eligibility here.